Evaluations & learnings

Evaluations provide independent assessments of our work, help us make adjustments and plan for the future.

Our evaluation framework is based on the internationally accepted evaluation framework of the Organization for Economic Co-operation and Development’s Development Assistance Committee, including its principles and criteria for grant evaluations. The framework was updated in 2022 to align with our 2023-2027 Strategy.

We require at least one evaluation for each investment or portfolio of investments, typically conducted within 12 months of closure. We also conduct prospective evaluations to facilitate real-time learning and thematic evaluations to review performance and capture learning within cross-cutting areas of our strategic framework.

Our evaluations are an integral part of the results framework, which provides more information on the tools and methods we use to quantify our impact.

Upcoming evaluations

  1. Portfolio Evaluation: New Tools for Vector Control (RFP Ref.  https://www.ungm.org/Public/Notice/294538)
  2. End of Project evaluation for Unitaid’s investment in Enabling preventive TB treatment in high-risk populations (Ref.: RFP 2025.15)
  3. Evaluation of Unitaid’s Portfolio of Investments in Accelerating Elimination of Cervical Cancer through Secondary Prevention” (Ref.: RFP 2025.18)

August 2026

Evaluation of Unitaid’s Portfolio of Investments in Accelerating Elimination of Cervical Cancer through Secondary Prevention: Annex 12. Country Case Studies – Burkina Faso, Kenya, Malawi and the Philippines

Evaluation report

Evaluation of Unitaid’s Portfolio of Investments in Accelerating Elimination of Cervical Cancer through Secondary Prevention – Vol. II

Evaluation report

Evaluation of Unitaid’s Portfolio of Investments in Accelerating Elimination of Cervical Cancer through Secondary Prevention – Evaluation Report, Vol. I

Evaluation report

July 2026

End of Project Evaluation for Unitaid’s Investment in Enabling TB Preventive Treatment in High-Risk Populations. Final Report

Final report

End of Project Evaluation for Unitaid’s Investment in Enabling TB Preventive Treatment in High-Risk Populations. Executive Summary

Executive summary

May 2026

End of Project evaluation for Unitaid’s investment in “Better tools for diagnosis and treatment of Plasmodium vivax malaria” Project (VivAction), Final Report

Final report

End of Project evaluation for Unitaid’s investment in “Better tools for diagnosis and treatment of Plasmodium vivax malaria” Project (VivAction), Country Case Studies

Evaluation report

December 2025

Unitaid Secretariat Management Response to the Unitaid 2023-2027. Strategy Mid-Term Review

Evaluation report
1 2 3 … 10